Referral care paths for non‐alcoholic fatty liver disease—Gearing up for an ever more prevalent and severe liver disease

Non‐alcoholic fatty liver disease (NAFLD) is an increasingly prevalent and potentially severe liver disease, emphasizing the need for implementation of widely supported care paths for patients at risk for advanced stages of NAFLD. In particular, the distinction of patients with a progressive and/or...

Full description

Saved in:
Bibliographic Details
Published in:United European gastroenterology journal 2021-10, Vol.9 (8), p.903-909
Main Authors: van Dijk, Anne‐Marieke, Schattenberg, Jörn M., Holleboom, Adriaan G., Tushuizen, Maarten E.
Format: Article
Language:English
Subjects:
Alcohol
Biopsy
Body mass index
care path
Critical Pathways
Diabetes
Fibrosis
guideline
Health risk assessment
Hepatitis
Hepatobiliary
hepatology
Humans
Liver - pathology
Liver cancer
Liver cirrhosis
Liver diseases
liver fibrosis
Medical personnel
Medical referrals
Metabolic syndrome
Mortality
Non-alcoholic Fatty Liver Disease - diagnosis
Non-alcoholic Fatty Liver Disease - epidemiology
Non-alcoholic Fatty Liver Disease - etiology
Non-alcoholic Fatty Liver Disease - therapy
non‐alcoholic fatty liver disease
Obesity
Patients
Practice Guidelines as Topic
Primary care
Referral and Consultation
Review
Risk factors
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Non‐alcoholic fatty liver disease (NAFLD) is an increasingly prevalent and potentially severe liver disease, emphasizing the need for implementation of widely supported care paths for patients at risk for advanced stages of NAFLD. In particular, the distinction of patients with a progressive and/or advanced, fibrotic NAFLD from those with simple steatosis requires improvement, as well as the awareness for NAFLD among health care professionals. Broad acceptance and implementation of interdisciplinary care paths in the near future will bring enhanced identification of those patients that benefit from surveillance, intensive lifestyle management, and empirical or investigational pharmacotherapy and enhance our epidemiological grasp of NAFLD in relation to lifestyle, genetic background, and cardiometabolic comorbidities related to NAFLD.
ISSN:2050-6406
2050-6414
DOI:10.1002/ueg2.12150